# Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer

Source: https://onco.cc/trials/nct06166589/  
OnCo record `nct06166589` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of zimberelimab, cAPOX (capecitabine, oxaliplatin), tegafur, gimeracil and oteracil (S-1) and fOLFIRI (5-FU, leucovorin, irinotecan) in pancreatic cancer, run by Shanghai Zhongshan Hospital, not yet recruiting.

## Summary

Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer is a phase 2, interventional study registered as NCT06166589 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 19 participants, started 2024-01-01 and due to reach its primary completion in 2026-01-01. Interventions recorded: Zimberelimab; Oxaliplatin; S-1; Irinotecan. Conditions listed: Previously AG Chemotherapy Treated Pancreatic Cancer. Primary outcome: ORR. Pancreatic eligibility wording from the registry: "* Patients with pancreatic cancer progressing after first-line AG regimen chemotherapy, including patients with advanced pancreatic cancer progressing after first-line AG regimen chemotherapy and patients with recurrence and metastasis after radical pancreatic cancer surgery assisted by AG regimen c". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06166589
- Phase: 2
- Setting: The Efficacy and Safety of Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer: A Prospective, Single Arm, Phase II Clinical Study
- Sponsor: Shanghai Zhongshan Hospital
- Enrolled: 19

## Sources

- ClinicalTrials.gov NCT06166589: https://clinicaltrials.gov/study/NCT06166589

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [Tegafur, gimeracil and oteracil (S-1)](https://onco.cc/drugs/tegafur-gimeracil-oteracil/), [Zimberelimab](https://onco.cc/drugs/zimberelimab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06166589.json